IL17A and chronic obstructive pulmonary disease: IL-17A can promote the activation of bronchial fibroblasts and epithelial cells to produce proinflammatory cytokines and recruit neutrophils and macrophages to sites of inflammation, aggravating the COPD progress (Halwani et al., 2013; Ponce-Gallegos et al., 2017).